2021 Annual Report launched

"Trading during the year reflected a sustained recovery in the industrial and medical laser markets and a robust performance from telecommunications and medical diagnostics. An increasingly productive R&D group delivered record levels of new product revenue during the year.

"There was some drag on the Group’s overall performance due to currency headwinds, self-isolation requirements and supply chain issues in parts of the business as we emerge from the pandemic. It was, however, a far better business environment than last year and we expect further improvement in the future.

Our restructuring programme is enhancing the Group’s margins and enabling us to better respond to our customers’ needs. We are committed to vigorously pursuing our long term strategic goals and will continue to invest in R&D and where appropriate, acquisitions.

"The Board remains confident that G&H is well positioned to deliver further progress in FY2022 and substantial long-term growth.”